PT  - JOURNAL ARTICLE
AU  - Karunamuni, Roshan
AU  - Huynh-Le, Minh-Phuong
AU  - Fan, Chun
AU  - Thompson, Wesley
AU  - Eeles, Rosalind
AU  - Kote-Jarai, Zsofia
AU  - Muir, Kenneth
AU - UKGPCS collaborators
AU  - Lophatananon, Artitaya
AU  - Tangen, Catherine
AU  - Goodman, Phyllis
AU  - Thompson, Ian
AU  - Blot, William
AU  - Zheng, Wei
AU  - Kibel, Adam
AU  - Drake, Bettina
AU  - Cussenot, Olivier
AU  - Cancel-Tassin, Geraldine
AU  - Menegaux, Florence
AU  - Truong, Therese
AU  - Park, Jong
AU  - Lin, Hui-Yi
AU  - Bensen, Jeannette
AU  - Fontham, Elizabeth
AU  - Mohler, James
AU  - Taylor, Jack
AU  - Multigner, Luc
AU  - Blanchet, Pascal
AU  - Brureau, Laurent
AU  - Romana, Marc
AU  - Leach, Robin
AU  - John, Esther
AU  - Fowke, Jay
AU  - Bush, William
AU  - Aldrich, Melinda
AU  - Crawford, Dana
AU  - Srivastava, Shiv
AU  - Cullen, Jennifer
AU  - Petrovics, Gyorgy
AU  - Parent, Marie-Elise
AU  - Hu, Jennifer
AU  - Sanderson, Maureen
AU  - Mills, Ian
AU  - Andreassen, Ole
AU  - Dale, Anders
AU  - Seibert, Tyler M
AU - The PRACTICAL Consortium
TI  - African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer
AID  - 10.1101/2020.04.20.20072926
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.20.20072926
4099  - http://medrxiv.org/content/early/2020/04/23/2020.04.20.20072926.short
4100  - http://medrxiv.org/content/early/2020/04/23/2020.04.20.20072926.full
AB  - Introduction Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46), showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify SNPs that might improve performance in this population.Material and Methods Anonymized genotypic data were obtained from the PRACTICAL consortium for 6,253 men with African genetic ancestry. Ten iterations of a ten-fold cross-validation search were conducted, to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and PHS46, and selected SNPs as predictors. The performance of PHS46 and PHS46+African were compared using the same cross-validated approach.Results Three SNPs (rs76229939, rs74421890, and rs5013678) were selected for inclusion in PHS46+African. All three SNPs are located on chromosome 8q24. PHS46+African showed substantial improvements in all performance metrics measured, including a 75% increase in the relative hazard of those in the upper 20% compared to the bottom 20% (2.47 to 4.34) and a 20% reduction in the relative hazard of those in the bottom 20% compared to the middle 40% (0.65 to 0.53).Conclusions We identified three SNPs that substantially improved the association of PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to levels comparable to Europeans and Asians. A strategy of building on established statistical models might benefit ancestral groups generally under-represented in genome-wide association studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received in support of the work presented.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this work were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, Readers who are interested in accessing the data must first submit a proposal to the Data Access Committee. If the reader is not a member of the consortium, their concept form must be sponsored by a principal investigator (PI) of one of the PRACTICAL consortium member studies. If approved by the Data Access Committee, PIs within the consortium, each of whom retains ownership of their data submitted to the consortium, can then choose to participate in the specific proposal. In addition, portions of the data are available for request from dbGaP (database of Genotypes and Phenotypes) which is maintained by the National Center for Biotechnology Information (NCBI): https://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostatehttps://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostate. Anyone can apply to join the consortium. The eligibility requirements are listed here: http://practical.icr.ac.uk/blog/?page_id=9. Joining the consortium would not guarantee access, as a proposal for access would still be submitted to the Data Access Committee, but there would be no need for a separate member sponsor. Readers may find information about application by using the contact information below: Rosalind Eeles Principal Investigator for PRACTICAL Professor of Oncogenetics Institute of Cancer Research (ICR) Sutton, UK Email: PRACTICAL@icr.ac.uk URL: http://practical.icr.ac.uk Tel: ++44 (0)20 8722 4094